Posted by Michael Wonder on 22 Feb 2021
FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
22 February 2021 - This is the third approval for Libtayo in the U.S.
The U.S. FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer whose tumours have high PD-L1 expression (tumour proportion score ≥50%), as determined by an FDA-approved test.
